RxDoctor Payments Data

Elizabeth Colaiocco

Family · Sparta, NJNPI 1396968996

Payments from drug & device makers

$3,117in general payments, 2019–2025

Across 54 payments — averaging $57.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myriad Women's Health, Inc.$1K
  • Axonics, Inc.$849
  • Astellas Pharma US Inc$629
  • Millicent US Inc$209
  • Bayer$62
  • Amgen$54
  • plus $216 from 8 others

What the payments were for

  • Speaking & faculty fees$1,00032%
  • Travel & lodging$37312%
  • Food & beverage$1,16237%
  • Education$58219%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Myriad Women's Health, Inc.3$1,099
Axonics, Inc.11$849
Astellas Pharma US Inc16$629
Millicent US Inc4$209
Bayer3$62
Amgen4$54
AbbVie2$45
Sumitomo Pharma America, Inc.2$37
Hollister Incorporated2$31
Pfizer2$30
Exeltis, USA Inc.2$30
ABC Home Medical Supply, Inc.1$16
Mayne Pharma Commercial LLC1$14
Avion Pharmaceuticals1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,117 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$37,806
Medicare patients
148
Services billed
879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron123$107,739
GemtesaVibegron29$29,141
PremarinEstrogens, Conjugated40$17,191
Darifenacin ErDarifenacin Hydrobromide50$12,918
Estradiol109$11,718
Fesoterodine Fumarate ErFesoterodine Fumarate41$7,161
Fosfomycin Tromethamine17$5,289
Methenamine Hippurate18$2,981
YuvafemEstradiol15$1,924
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst49$713
Trimethoprim12$620
Oxybutynin Chloride ErOxybutynin Chloride13$411
CefuroximeCefuroxime Axetil28$314
Betamethasone Dipropionate12$296
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet22$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$629$107,739123 claims
Sumitomo Pharma America, Inc.Gemtesa$37$29,14129 claims
PfizerPremarin$30$17,19140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in Sparta

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →